Literature DB >> 24091506

Curbing our enthusiasm for fecal transplantation in ulcerative colitis.

David T Rubin1.   

Abstract

Given the known dysbiosis of gut microflora in inflammatory bowel disease, there has been great enthusiasm about the potential for fecal microbiota transplantation (FMT) as a treatment. This editorial accompanies a prospective series of five patients with ulcerative colitis who underwent FMT, but did not achieve remission. I discuss the important observations from this study and point out that the lack of clinical efficacy and observed side effects warrant caution in the ongoing pursuit of this treatment option.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24091506     DOI: 10.1038/ajg.2013.279

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  10 in total

Review 1.  Complementary and Alternative Medicine Strategies for Therapeutic Gut Microbiota Modulation in Inflammatory Bowel Disease and their Next-Generation Approaches.

Authors:  Abigail R Basson; Minh Lam; Fabio Cominelli
Journal:  Gastroenterol Clin North Am       Date:  2017-12       Impact factor: 3.806

Review 2.  The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions.

Authors:  Stephen M Vindigni; Timothy L Zisman; David L Suskind; Christopher J Damman
Journal:  Therap Adv Gastroenterol       Date:  2016-04-19       Impact factor: 4.409

Review 3.  Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies.

Authors:  Lauren E Hudson; Sarah E Anderson; Anita H Corbett; Tracey J Lamb
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 4.  Enteric microbiota leads to new therapeutic strategies for ulcerative colitis.

Authors:  Wei-Xu Chen; Li-Hua Ren; Rui-Hua Shi
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 5.  Treatment of IBD: where we are and where we are going.

Authors:  Charles N Bernstein
Journal:  Am J Gastroenterol       Date:  2014-12-09       Impact factor: 10.864

Review 6.  Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis.

Authors:  Ruben J Colman; David T Rubin
Journal:  J Crohns Colitis       Date:  2014-09-13       Impact factor: 10.020

Review 7.  Mucosal Immune Development in Early Life: Setting the Stage.

Authors:  Sylvia Brugman; Olaf Perdijk; R J Joost van Neerven; Huub F J Savelkoul
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2015-02-11       Impact factor: 4.291

Review 8.  Fecal microbiota transplantation in inflammatory bowel disease: beyond the excitement.

Authors:  Gianluca Ianiro; Stefano Bibbò; Franco Scaldaferri; Antonio Gasbarrini; Giovanni Cammarota
Journal:  Medicine (Baltimore)       Date:  2014-10       Impact factor: 1.889

9.  Fecal transplantation - the new, inexpensive, safe, and rapidly effective approach in the treatment of gastrointestinal tract diseases.

Authors:  R Oprita; M Bratu; B Oprita; B Diaconescu
Journal:  J Med Life       Date:  2016 Apr-Jun

10.  A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis.

Authors:  Matthew R Henn; Edward J O'Brien; Liyang Diao; Brian G Feagan; William J Sandborn; Curtis Huttenhower; Jennifer R Wortman; Barbara H McGovern; Sherry Wang-Weigand; David I Lichter; Meghan Chafee; Christopher B Ford; Patricia Bernardo; Peng Zhao; Sheri Simmons; Amelia D Tomlinson; David N Cook; Roger J Pomerantz; Bharat K Misra; John G Auninš; Michele Trucksis
Journal:  Gastroenterology       Date:  2020-08-04       Impact factor: 22.682

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.